Abstract:PDF file - 794KB, Immunosuppressive effect of another constitutive IDO-expressing MSC clone MSC-IDOc2 (S1); Expression of iNOS or IDO in MSCs upon cytokine stimulation and their effect on lymphocyte proliferation (S2); Effect of iNOS-/- MSCs on proliferation of activated human peripheral blood mononuclear cells (S3); In Situ expression and location of human IDO in the tumor tissue (S4); Effect of IDO-expressing MSCs on the distribution of immune cell subpopulations in peripheral blood and tumor tissues (S5); Effect of IDO-expressing MSCs on the distribution of immune cell subpopulations in peripheral blood and tumor tissues (S6); Effect of IDO-expressing MSCs on the distribution of immune cell subpopulations in peripheral blood and tumor tissues (S7).

Supplementary Figure Legends and Supplementary Figures 1 Through 4 from A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies

Supplementary Figure Legends from Intracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells

Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

Supplementary Figure S4 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Supplementary Figure 4 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

Supplementary Figure Legends from EpCAM Inhibition Sensitizes Chemoresistant Leukemia to Immune Surveillance

Supplementary Figure Legends from Mesenchymal Stem Cells Use IDO to Regulate Immunity in Tumor Microenvironment

Supplementary Figure Legends 1-6, Methods from Pivotal Role of Reduced <i>let-7g</i> Expression in Breast Cancer Invasion and Metastasis

Supplementary Figure Legends from NK Cell–Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines

Supplementary Materials and Methods, Supplementary Figure Legends, and Supplementary Tables 1 through 5 from SSBP1 Suppresses TGFβ-Driven Epithelial-to-Mesenchymal Transition and Metastasis in Triple-Negative Breast Cancer by Regulating Mitochondrial Retrograde Signaling

Supplementary Figure Legends from Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer

Supplementary Figures 1 - 7 from Mesenchymal Stem Cells Use IDO to Regulate Immunity in Tumor Microenvironment

Supplementary Figure Legend from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Supplementary Methods, Figure Legends 1-3 from Molecular Target Characterization and Antimyeloma Activity of the Novel, Insulin-like Growth Factor 1 Receptor Inhibitor, GTx-134

Supplementary Methods and Figure legends from Reducing CD73 Expression by IL1β-Programmed Th17 Cells Improves Immunotherapeutic Control of Tumors

Supplementary Figure Legends 1-8 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Supplementary Figure Legend from CCL9 Induced by TGFβ Signaling in Myeloid Cells Enhances Tumor Cell Survival in the Premetastatic Organ

Supplementary Figure 2 from Combining DNA Vaccine and AIDA-1 in Attenuated Salmonella Activates Tumor-Specific CD4+ and CD8+ T-cell Responses

Supplementary Figure Legends from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance Via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Supplementary Figure and Table Legends from Novel STAT3 Phosphorylation Inhibitors Exhibit Potent Growth-Suppressive Activity in Pancreatic and Breast Cancer Cells